Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: tinzaparin sodium Clear all
Completed Phase 2Phase 3 Interventional

Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)

NCT04372589
View directory record Official record
Conditions
COVID-19, Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Atlanta, Georgia • Chicago, Illinois • Jefferson, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 28, 2026, 6:10 PM EDT
Completed No phase listed Observational

Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients

NCT01727427
View directory record Official record
Conditions
Unsuspected Pulmonary Embolism
Interventions
Heparin, fondaparinux, vitamin-K antagonists, aspirin
Drug
Lead sponsor
G. d'Annunzio University
Other
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Sep 28, 2026, 6:10 PM EDT
Terminated Phase 2 Interventional

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

NCT00981903
View directory record Official record
Conditions
Venous Thromboembolism, Cancer
Interventions
Tinzaparin sodium
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 28, 2026, 6:10 PM EDT
Completed No phase listed Observational

Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort

NCT04979780
View directory record Official record
Conditions
Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,708 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Multiple Locations, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 28, 2026, 6:10 PM EDT
Terminated Phase 2 Interventional

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

NCT01518465
View directory record Official record
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
dalteparin, lenalidomide, dexamethasone, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

NCT00679588
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin Sodium, Enoxaparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Corlton, California • Huntingdon Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 28, 2026, 6:10 PM EDT
Terminated Phase 3 Interventional

Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism

NCT01164046
View directory record Official record
Conditions
Venous Thromboembolism, Neoplasms
Interventions
low molecular weight heparin, vitamin K antagonists
Drug
Lead sponsor
University Medical Center Groningen
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Not applicable Interventional Results available

The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma

NCT01050153
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Dalteparin sodium, Dalteparin sodium/aspirin
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Phase 4 Interventional

Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy

NCT01828697
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Low dose nadroparin, Intermediate dose nadroparin, Low dose enoxaparin, Intermediate dose enoxaparin, Low dose dalteparin, Intermediate dose dalteparin, Fixed low dose tinzaparin, Intermediate dose tinzaparin
Drug
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery

NCT00718224
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin sodium, Enoxaparin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Upper Extremity Deep-Vein Thrombosis

NCT00245856
View directory record Official record
Conditions
Deep-Vein Thrombosis
Interventions
Dalteparin sodium injection, Warfarin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Sep 28, 2026, 6:10 PM EDT
Terminated Phase 3 Interventional Results available

Clot Dissolving Treatment for Blood Clots in the Lungs

NCT00680628
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Tenecteplase + Enoxaparin, 0.9% Saline + Enoxaparin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
7
States / cities
Sacramento, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Sep 28, 2026, 6:10 PM EDT
Withdrawn Phase 4 Interventional

Timing of VTE Prophylaxis in TBI

NCT03081169
View directory record Official record
Conditions
TBI (Traumatic Brain Injury), VTE (Venous Thromboembolism)
Interventions
Enoxaparin Sodium 150 MG/ML Prefilled Syringe, Heparin
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Sep 28, 2026, 6:10 PM EDT
Not listed Phase 4 Interventional

Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

NCT02342444
View directory record Official record
Conditions
Trauma, Surgery, Deep Vein Thrombosis (DVT), Thromboembolic Events
Interventions
Enoxaparin Sodium Injection 30 mg BID, Enoxaparin Sodium Injection 40 mg QD
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 100 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Early Phase 1 Interventional

Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients

NCT00894283
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Fondaparinux
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer

NCT00942968
View directory record Official record
Conditions
Cancer
Interventions
dalteparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
21
States / cities
Tucson, Arizona • Pleasant Hill, California • Torrance, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Phase 4 Interventional

PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)

NCT00077805
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Enoxaparin sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 28, 2026, 6:10 PM EDT
Recruiting Phase 3 Interventional

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

NCT05848713
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 28, 2026, 6:10 PM EDT
Terminated Phase 1Phase 2 Interventional

Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)

NCT02744833
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
GMI-1271, Enoxaparin Sodium (Lovenox®)
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 28, 2026, 6:10 PM EDT
Completed Phase 3 Interventional Results available

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

NCT00790335
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism, Post Thrombotic Syndrome
Interventions
Recombinant tissue plasminogen activator (rt-PA)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
16 Years to 75 Years
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
56
States / cities
Glendale, Arizona • Orange, California • Stanford, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 28, 2026, 6:10 PM EDT